Published online Oct 6, 2020. doi: 10.12998/wjcc.v8.i19.4380
Peer-review started: June 16, 2020
First decision: July 24, 2020
Revised: July 27, 2020
Accepted: August 26, 2020
Article in press: August 26, 2020
Published online: October 6, 2020
Processing time: 97 Days and 19 Hours
It is not known whether percutaneous radiofrequency ablation (PRFA) has the same treatment efficacy and fewer complications than laparoscopic resection in patients with small centrally located hepatocellular carcinoma (HCC).
This retrospective study aimed to compare the effectiveness of PRFA with classical laparoscopic resection in patients with small HCC and document the safety parameters, to provide an experimental basis for the clinical treatment of small HCC.
To determine whether PRFA has the same effect as surgical resection with fewer complications in patients with small HCC, in order to provide more specific options for HCC treatment.
In this retrospective study, 85 patients treated with hepatic resection and 90 PRFA-treated patients were enrolled in our hospital from July 2016 to July 2019, Treatment outcomes, including major complications and survival data, were determined.
The results showed that minor differences existed in the baseline characteristics between the patients in the two groups. PRFA significantly increased cumulative recurrence-free survival (hazard ratio 1.048, 95%CI: 0.265–3.268) and overall survival (hazard ratio 0.126, 95%CI: 0.025–0.973); PRFA had a lower rate of major complications than HR (7.78 vs 20.0%, P < 0.05), and the hospital stay was also shorter in the PRFA group than in the HR group (7.8 ± 0.2 d vs 9.5 ± 0.3 d, P < 0.001).
Based on the data obtained, we conclude that PRFA was superior to hepatic resection and may reduce complications and hospital stay in patients with small HCC.
The clinical application of PFRA should be increased to prove PFRA as the standard treatment for patients with small HCC.